
Annual report 2022
added 12-27-2025
AnPac Bio-Medical Science Co., Ltd. Net Income 2011-2026 | ANPC
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income AnPac Bio-Medical Science Co., Ltd.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -102 M | -119 M | -80.5 M | -101 M | -42.1 M | -39.1 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -39.1 M | -119 M | -80.5 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-62.9 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
-384 M | $ 219.68 | 1.92 % | $ 5 B | ||
|
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | ||
|
Seres Therapeutics
MCRB
|
-114 M | $ 8.28 | - | $ 1.06 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 19.45 | 1.14 % | $ 909 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | ||
|
Mesoblast Limited
MESO
|
-91.3 M | $ 15.44 | 7.82 % | $ 10 B | ||
|
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-212 M | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - | ||
|
Cara Therapeutics
CARA
|
-119 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-16.6 M | $ 0.67 | -5.25 % | $ 7.67 M | ||
|
Mirum Pharmaceuticals
MIRM
|
-23.4 M | $ 90.39 | 2.86 % | $ 4.54 B | ||
|
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-221 M | $ 1.34 | 1.52 % | $ 342 M | ||
|
MediciNova
MNOV
|
-12 M | $ 1.45 | - | $ 71.1 M | ||
|
CytomX Therapeutics
CTMX
|
-17.4 M | $ 4.37 | 2.95 % | $ 603 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
-11.2 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
-132 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
-13.6 M | $ 2.69 | 1.37 % | $ 16.9 M | ||
|
Dynavax Technologies Corporation
DVAX
|
27.3 M | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
-178 M | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Merck & Co.
MRK
|
18.3 B | $ 117.56 | 1.02 % | $ 294 B | ||
|
Marker Therapeutics
MRKR
|
-12.2 M | $ 1.37 | 8.73 % | $ 21 M | ||
|
Moderna
MRNA
|
-2.82 B | $ 53.09 | 3.41 % | $ 20.7 B | ||
|
Bellerophon Therapeutics
BLPH
|
-19.8 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-33.5 M | $ 4.47 | 3.71 % | $ 856 M | ||
|
Homology Medicines
FIXX
|
29.8 M | - | 0.77 % | $ 53.4 M |